Dapsone as first line therapy for bullous pemphigoid.
In an open study, a total of 18 patients with proven bullous pemphigoid (16 new patients and two in relapse) were treated with a trial of dapsone (17 patients) or sulphonimide (one patient). Overall, eight patients were controlled on one of these agents as the sole treatment (44%). Six patients had...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1989
|
| _version_ | 1826276865781792768 |
|---|---|
| author | Venning, V Millard, P Wojnarowska, F |
| author_facet | Venning, V Millard, P Wojnarowska, F |
| author_sort | Venning, V |
| collection | OXFORD |
| description | In an open study, a total of 18 patients with proven bullous pemphigoid (16 new patients and two in relapse) were treated with a trial of dapsone (17 patients) or sulphonimide (one patient). Overall, eight patients were controlled on one of these agents as the sole treatment (44%). Six patients had a partial, but inadequate response, while four did not respond. The responses to the sulpha drugs were generally rapid, i.e. within 2 weeks, and the maximum doses used in any patient were 100 mg/day dapsone and 1.5 g/day of sulphapyridine or sulphamethoxypyridazine. Significant side-effects to dapsone occurred in six of the 17 patients. A trial of a sulphone or sulphonamide drug is warranted in bullous pemphigoid both as an initial treatment or in the treatment of relapse, particularly when there is a contraindication to the use of corticosteroids. Side-effects are common and therapy needs to be closely monitored. |
| first_indexed | 2024-03-06T23:20:16Z |
| format | Journal article |
| id | oxford-uuid:687f91e7-d1ee-42b7-bb03-532d86d0e80f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:20:16Z |
| publishDate | 1989 |
| record_format | dspace |
| spelling | oxford-uuid:687f91e7-d1ee-42b7-bb03-532d86d0e80f2022-03-26T18:45:09ZDapsone as first line therapy for bullous pemphigoid.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:687f91e7-d1ee-42b7-bb03-532d86d0e80fEnglishSymplectic Elements at Oxford1989Venning, VMillard, PWojnarowska, FIn an open study, a total of 18 patients with proven bullous pemphigoid (16 new patients and two in relapse) were treated with a trial of dapsone (17 patients) or sulphonimide (one patient). Overall, eight patients were controlled on one of these agents as the sole treatment (44%). Six patients had a partial, but inadequate response, while four did not respond. The responses to the sulpha drugs were generally rapid, i.e. within 2 weeks, and the maximum doses used in any patient were 100 mg/day dapsone and 1.5 g/day of sulphapyridine or sulphamethoxypyridazine. Significant side-effects to dapsone occurred in six of the 17 patients. A trial of a sulphone or sulphonamide drug is warranted in bullous pemphigoid both as an initial treatment or in the treatment of relapse, particularly when there is a contraindication to the use of corticosteroids. Side-effects are common and therapy needs to be closely monitored. |
| spellingShingle | Venning, V Millard, P Wojnarowska, F Dapsone as first line therapy for bullous pemphigoid. |
| title | Dapsone as first line therapy for bullous pemphigoid. |
| title_full | Dapsone as first line therapy for bullous pemphigoid. |
| title_fullStr | Dapsone as first line therapy for bullous pemphigoid. |
| title_full_unstemmed | Dapsone as first line therapy for bullous pemphigoid. |
| title_short | Dapsone as first line therapy for bullous pemphigoid. |
| title_sort | dapsone as first line therapy for bullous pemphigoid |
| work_keys_str_mv | AT venningv dapsoneasfirstlinetherapyforbullouspemphigoid AT millardp dapsoneasfirstlinetherapyforbullouspemphigoid AT wojnarowskaf dapsoneasfirstlinetherapyforbullouspemphigoid |